MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 253 filers reported holding MYRIAD GENETICS INC in Q4 2017. The put-call ratio across all filers is 0.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,178,000 | -59.3% | 34,298 | -57.1% | 0.02% | -65.4% |
| Q3 2017 | $2,891,000 | +123.2% | 79,904 | +59.3% | 0.05% | +85.7% |
| Q2 2017 | $1,295,000 | -14.5% | 50,151 | -36.4% | 0.03% | -15.2% |
| Q1 2017 | $1,515,000 | +41.9% | 78,911 | +23.1% | 0.03% | 0.0% |
| Q4 2016 | $1,068,000 | +51.7% | 64,093 | +87.4% | 0.03% | +26.9% |
| Q3 2016 | $704,000 | +45.2% | 34,205 | +116.0% | 0.03% | 0.0% |
| Q2 2016 | $485,000 | +61.1% | 15,839 | +97.0% | 0.03% | +36.8% |
| Q1 2016 | $301,000 | -88.5% | 8,041 | -86.7% | 0.02% | -90.6% |
| Q4 2015 | $2,615,000 | +567.1% | 60,582 | +478.9% | 0.20% | +225.8% |
| Q3 2015 | $392,000 | -92.4% | 10,465 | -93.1% | 0.06% | -69.8% |
| Q2 2015 | $5,152,000 | -4.8% | 151,562 | -0.9% | 0.20% | -5.1% |
| Q1 2015 | $5,414,000 | +122.8% | 152,946 | +114.4% | 0.22% | +72.8% |
| Q4 2014 | $2,430,000 | +494.1% | 71,353 | +572.4% | 0.12% | +290.6% |
| Q3 2014 | $409,000 | – | 10,611 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 5,000,000 | $90,850,000 | 3.94% |
| Altium Capital Management LP | 221,000 | $4,016,000 | 1.61% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,900,787 | $34,537,000 | 0.93% |
| Zebra Capital Management LLC | 15,352 | $279,000 | 0.82% |
| PFM Health Sciences, LP | 1,177,250 | $21,391,000 | 0.82% |
| EARNEST PARTNERS LLC | 6,462,138 | $117,417,000 | 0.78% |
| Glenview Capital Management | 1,696,791 | $30,831,000 | 0.77% |
| AIMZ Investment Advisors, LLC | 42,085 | $765,000 | 0.37% |
| Phocas Financial Corp. | 127,949 | $2,325,000 | 0.35% |
| Redhawk Wealth Advisors, Inc. | 34,680 | $630,000 | 0.29% |